| Lipids Management |
1 |
1 |
| PCSK9 |
0 |
0.94 |
| Cardiovascular Risk Management |
0 |
0.66 |
| Statins |
0 |
0.54 |
| LDL Cholesterol |
0 |
0.9 |
| High Density Lipoprotein (HDL) cholesterol |
0 |
0.16 |
| Cardiovascular disease |
0 |
0.15 |
| Cerebrovascular Accident |
0 |
0.15 |
| Infarction |
0 |
0.15 |
| Jobs |
0 |
0.15 |
| Lipoproteins |
0 |
0.15 |
| Medical Life |
0 |
0.15 |
| Myocardial Infarction (MI) |
0 |
0.15 |
| Pollex |
0 |
0.15 |
| Familial Hypercholesterolemia |
0 |
0.11 |
| Apolipoproteins |
0 |
0.08 |
| Biologic Therapy |
0 |
0.08 |
| Body Mass Index |
0 |
0.08 |
| Clinical Guidelines |
0 |
0.08 |
| Europe |
0 |
0.08 |
| Heart |
0 |
0.08 |
| Hypercholesterolemia |
0 |
0.08 |
| Monoclonal Antibody |
0 |
0.08 |
| Travel Medicine |
0 |
0.08 |
| Virginia |
0 |
0.08 |